Delhi’s Air Quality Today: Pollution Levels Remain Severe Delhi continues to struggle with severely polluted air today , making breathing uncomfortable and risky for millions of residents. The Air Quality Index (AQI in the city is around 360 , which falls under the “Severe” category. At this level, the air is harmful for everyone , not just those with existing health conditions. What Does Today’s AQI of 360 Indicate? An AQI reading of 360 means the concentration of harmful pollutants in the air is extremely high. Prolonged exposure at this level can cause serious health issues, including breathing difficulty, irritation in the eyes and throat, headaches, and fatigue. Even short-term outdoor exposure is not advisable when AQI crosses this range. Understanding the AQI Scale (Simple Explanation) Here’s what AQI numbers generally mean: 0–50 (Good): Air quality is clean and safe for everyone. 51–100 (Satisfactory / Moderate): Acceptable air quality; minor...
Corona Remedies Shares Make Strong Market Debut, Deliver Solid Gains to IPO Investors
Corona Remedies made an impressive entry into the stock market today, rewarding IPO investors with strong listing gains as the pharmaceutical company debuted at a significant premium over its issue price. The positive debut reflects healthy demand for the stock and growing investor confidence in the domestic pharma space.
Strong Listing on NSE
Corona Remedies shares listed on the NSE at around ₹486 per share, marking a premium of over 38% compared to the IPO issue price of ₹351 per share. The sharp jump at the opening bell immediately put the stock in focus among traders and long-term investors alike.
Following the listing, the stock witnessed active buying interest and held firm above its issue price, indicating sustained demand beyond just listing-day enthusiasm.
How Much IPO Investors Made
For investors who received allotment, the gains were clearly visible from the start:
Issue Price: ₹351 per share
Listing Price: ₹486 per share
Gain per Share: ₹135
With the IPO lot size fixed at 42 shares, the gains per lot worked out to:
Investment per lot: ₹14,742
Value at listing: ₹20,412
Profit per lot: approximately ₹5,670
This translates into a return of nearly 38% on listing day, making Corona Remedies one of the better-performing recent pharma IPOs.
Intraday Performance and Market Response
Post listing, the stock traded with healthy volumes, reflecting participation from both retail and institutional investors. Pharma stocks have been in favour amid steady demand for healthcare products, and Corona Remedies appears to have benefited from this broader sector momentum.
The absence of immediate heavy profit-booking suggests that many investors are viewing the company as a medium-to-long-term opportunity rather than a pure listing-day trade.
Why the Stock Attracted Demand
Several factors supported the strong debut:
Established domestic pharma presence with a diversified product portfolio
Consistent revenue growth in recent years
Focus on chronic therapies, which provide stable demand
Reasonable IPO pricing, leaving room for listing gains
The company’s positioning in the Indian pharmaceutical market helped it stand out at a time when investors are selectively favouring quality healthcare names.
What Investors Should Watch Next
While the listing performance has been encouraging, investors should now shift focus to fundamentals and execution:
Quarterly earnings growth and margin stability
Product pipeline and expansion plans
Regulatory compliance and competitive pressure
Overall sentiment in the pharma sector
Short-term traders may see volatility as some investors book profits, while long-term investors may look for price consolidation before adding positions.
Final Take
Corona Remedies’ stock market debut has clearly rewarded IPO investors with strong and immediate gains. A nearly 38% premium at listing, healthy volumes, and stable post-listing trade indicate solid investor confidence in the company’s business model.
Whether the stock can build on this momentum will depend on its ability to deliver consistent financial performance in the coming quarters. For now, Corona Remedies has started its listed journey on a strong and positive note.
Comments
Post a Comment